img

Global Anti-VEGF Therapeutic Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Anti-VEGF Therapeutic Market Insights, Forecast to 2034

Anti–vascular endothelial growth factor therapy, also known as anti-VEGF therapy or medication, is the use of medications that block vascular endothelial growth factor.
Global Anti-VEGF Therapeutic market is expected to reach to US$ 887 million in 2024, with a positive growth of %, compared with US$ 833 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Anti-VEGF Therapeutic industry is evaluated to reach US$ 1316.3 million in 2029. The CAGR will be 6.8% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Anti-VEGF Therapeutic market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Anti-VEGF Therapeutic market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Regeneron Pharmaceuticals
Bayer
Novartis
Roche
Biogen
Pfizer
Coherus BioSciences
Amgen
Bausch Health Companies
Viatris
Segment by Type
Aflibercept (Eylea)
Ranibizumab (Lucentis)
Brolucizumab (Beovu)
Others

Segment by Application


Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-related Macular Degeneration
Others

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Anti-VEGF Therapeutic plant distribution, commercial date of Anti-VEGF Therapeutic, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Anti-VEGF Therapeutic introduction, etc. Anti-VEGF Therapeutic Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Anti-VEGF Therapeutic
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Anti-VEGF Therapeutic Product Introduction
1.2 Market by Type
1.2.1 Global Anti-VEGF Therapeutic Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Aflibercept (Eylea)
1.2.3 Ranibizumab (Lucentis)
1.2.4 Brolucizumab (Beovu)
1.2.5 Others
1.3 Market by Application
1.3.1 Global Anti-VEGF Therapeutic Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Macular Edema
1.3.3 Diabetic Retinopathy
1.3.4 Retinal Vein Occlusion
1.3.5 Age-related Macular Degeneration
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Anti-VEGF Therapeutic Sales Estimates and Forecasts 2018-2029
2.2 Global Anti-VEGF Therapeutic Revenue by Region
2.2.1 Global Anti-VEGF Therapeutic Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Anti-VEGF Therapeutic Revenue by Region (2018-2024)
2.2.3 Global Anti-VEGF Therapeutic Revenue by Region (2024-2029)
2.2.4 Global Anti-VEGF Therapeutic Revenue Market Share by Region (2018-2029)
2.3 Global Anti-VEGF Therapeutic Sales Estimates and Forecasts 2018-2029
2.4 Global Anti-VEGF Therapeutic Sales by Region
2.4.1 Global Anti-VEGF Therapeutic Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Anti-VEGF Therapeutic Sales by Region (2018-2024)
2.4.3 Global Anti-VEGF Therapeutic Sales by Region (2024-2029)
2.4.4 Global Anti-VEGF Therapeutic Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Anti-VEGF Therapeutic Sales by Manufacturers
3.1.1 Global Anti-VEGF Therapeutic Sales by Manufacturers (2018-2024)
3.1.2 Global Anti-VEGF Therapeutic Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Anti-VEGF Therapeutic in 2022
3.2 Global Anti-VEGF Therapeutic Revenue by Manufacturers
3.2.1 Global Anti-VEGF Therapeutic Revenue by Manufacturers (2018-2024)
3.2.2 Global Anti-VEGF Therapeutic Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Anti-VEGF Therapeutic Revenue in 2022
3.3 Global Key Players of Anti-VEGF Therapeutic, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Anti-VEGF Therapeutic Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-VEGF Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-VEGF Therapeutic, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-VEGF Therapeutic, Product Offered and Application
3.8 Global Key Manufacturers of Anti-VEGF Therapeutic, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Anti-VEGF Therapeutic Sales by Type
4.1.1 Global Anti-VEGF Therapeutic Historical Sales by Type (2018-2024)
4.1.2 Global Anti-VEGF Therapeutic Forecasted Sales by Type (2024-2029)
4.1.3 Global Anti-VEGF Therapeutic Sales Market Share by Type (2018-2029)
4.2 Global Anti-VEGF Therapeutic Revenue by Type
4.2.1 Global Anti-VEGF Therapeutic Historical Revenue by Type (2018-2024)
4.2.2 Global Anti-VEGF Therapeutic Forecasted Revenue by Type (2024-2029)
4.2.3 Global Anti-VEGF Therapeutic Revenue Market Share by Type (2018-2029)
4.3 Global Anti-VEGF Therapeutic Price by Type
4.3.1 Global Anti-VEGF Therapeutic Price by Type (2018-2024)
4.3.2 Global Anti-VEGF Therapeutic Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Anti-VEGF Therapeutic Sales by Application
5.1.1 Global Anti-VEGF Therapeutic Historical Sales by Application (2018-2024)
5.1.2 Global Anti-VEGF Therapeutic Forecasted Sales by Application (2024-2029)
5.1.3 Global Anti-VEGF Therapeutic Sales Market Share by Application (2018-2029)
5.2 Global Anti-VEGF Therapeutic Revenue by Application
5.2.1 Global Anti-VEGF Therapeutic Historical Revenue by Application (2018-2024)
5.2.2 Global Anti-VEGF Therapeutic Forecasted Revenue by Application (2024-2029)
5.2.3 Global Anti-VEGF Therapeutic Revenue Market Share by Application (2018-2029)
5.3 Global Anti-VEGF Therapeutic Price by Application
5.3.1 Global Anti-VEGF Therapeutic Price by Application (2018-2024)
5.3.2 Global Anti-VEGF Therapeutic Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Anti-VEGF Therapeutic Market Size by Type
6.1.1 US & Canada Anti-VEGF Therapeutic Sales by Type (2018-2029)
6.1.2 US & Canada Anti-VEGF Therapeutic Revenue by Type (2018-2029)
6.2 US & Canada Anti-VEGF Therapeutic Market Size by Application
6.2.1 US & Canada Anti-VEGF Therapeutic Sales by Application (2018-2029)
6.2.2 US & Canada Anti-VEGF Therapeutic Revenue by Application (2018-2029)
6.3 US & Canada Anti-VEGF Therapeutic Market Size by Country
6.3.1 US & Canada Anti-VEGF Therapeutic Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Anti-VEGF Therapeutic Sales by Country (2018-2029)
6.3.3 US & Canada Anti-VEGF Therapeutic Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Anti-VEGF Therapeutic Market Size by Type
7.1.1 Europe Anti-VEGF Therapeutic Sales by Type (2018-2029)
7.1.2 Europe Anti-VEGF Therapeutic Revenue by Type (2018-2029)
7.2 Europe Anti-VEGF Therapeutic Market Size by Application
7.2.1 Europe Anti-VEGF Therapeutic Sales by Application (2018-2029)
7.2.2 Europe Anti-VEGF Therapeutic Revenue by Application (2018-2029)
7.3 Europe Anti-VEGF Therapeutic Market Size by Country
7.3.1 Europe Anti-VEGF Therapeutic Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Anti-VEGF Therapeutic Sales by Country (2018-2029)
7.3.3 Europe Anti-VEGF Therapeutic Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Anti-VEGF Therapeutic Market Size
8.1.1 China Anti-VEGF Therapeutic Sales (2018-2029)
8.1.2 China Anti-VEGF Therapeutic Revenue (2018-2029)
8.2 China Anti-VEGF Therapeutic Market Size by Application
8.2.1 China Anti-VEGF Therapeutic Sales by Application (2018-2029)
8.2.2 China Anti-VEGF Therapeutic Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Anti-VEGF Therapeutic Market Size by Type
9.1.1 Asia Anti-VEGF Therapeutic Sales by Type (2018-2029)
9.1.2 Asia Anti-VEGF Therapeutic Revenue by Type (2018-2029)
9.2 Asia Anti-VEGF Therapeutic Market Size by Application
9.2.1 Asia Anti-VEGF Therapeutic Sales by Application (2018-2029)
9.2.2 Asia Anti-VEGF Therapeutic Revenue by Application (2018-2029)
9.3 Asia Anti-VEGF Therapeutic Sales by Region
9.3.1 Asia Anti-VEGF Therapeutic Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Anti-VEGF Therapeutic Revenue by Region (2018-2029)
9.3.3 Asia Anti-VEGF Therapeutic Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-VEGF Therapeutic Market Size by Type
10.1.1 Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Anti-VEGF Therapeutic Market Size by Application
10.2.1 Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales by Country
10.3.1 Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Regeneron Pharmaceuticals
11.1.1 Regeneron Pharmaceuticals Company Information
11.1.2 Regeneron Pharmaceuticals Overview
11.1.3 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Regeneron Pharmaceuticals Recent Developments
11.2 Bayer
11.2.1 Bayer Company Information
11.2.2 Bayer Overview
11.2.3 Bayer Anti-VEGF Therapeutic Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Bayer Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bayer Recent Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Overview
11.3.3 Novartis Anti-VEGF Therapeutic Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Novartis Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Novartis Recent Developments
11.4 Roche
11.4.1 Roche Company Information
11.4.2 Roche Overview
11.4.3 Roche Anti-VEGF Therapeutic Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Roche Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Roche Recent Developments
11.5 Biogen
11.5.1 Biogen Company Information
11.5.2 Biogen Overview
11.5.3 Biogen Anti-VEGF Therapeutic Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Biogen Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Biogen Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Overview
11.6.3 Pfizer Anti-VEGF Therapeutic Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Pfizer Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Pfizer Recent Developments
11.7 Coherus BioSciences
11.7.1 Coherus BioSciences Company Information
11.7.2 Coherus BioSciences Overview
11.7.3 Coherus BioSciences Anti-VEGF Therapeutic Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Coherus BioSciences Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Coherus BioSciences Recent Developments
11.8 Amgen
11.8.1 Amgen Company Information
11.8.2 Amgen Overview
11.8.3 Amgen Anti-VEGF Therapeutic Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Amgen Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Amgen Recent Developments
11.9 Bausch Health Companies
11.9.1 Bausch Health Companies Company Information
11.9.2 Bausch Health Companies Overview
11.9.3 Bausch Health Companies Anti-VEGF Therapeutic Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Bausch Health Companies Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Bausch Health Companies Recent Developments
11.10 Viatris
11.10.1 Viatris Company Information
11.10.2 Viatris Overview
11.10.3 Viatris Anti-VEGF Therapeutic Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Viatris Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Viatris Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Anti-VEGF Therapeutic Industry Chain Analysis
12.2 Anti-VEGF Therapeutic Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-VEGF Therapeutic Production Mode & Process
12.4 Anti-VEGF Therapeutic Sales and Marketing
12.4.1 Anti-VEGF Therapeutic Sales Channels
12.4.2 Anti-VEGF Therapeutic Distributors
12.5 Anti-VEGF Therapeutic Customers
13 Market Dynamics
13.1 Anti-VEGF Therapeutic Industry Trends
13.2 Anti-VEGF Therapeutic Market Drivers
13.3 Anti-VEGF Therapeutic Market Challenges
13.4 Anti-VEGF Therapeutic Market Restraints
14 Key Findings in The Global Anti-VEGF Therapeutic Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-VEGF Therapeutic Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Aflibercept (Eylea)
Table 3. Major Manufacturers of Ranibizumab (Lucentis)
Table 4. Major Manufacturers of Brolucizumab (Beovu)
Table 5. Major Manufacturers of Others
Table 6. Global Anti-VEGF Therapeutic Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Anti-VEGF Therapeutic Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Anti-VEGF Therapeutic Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Anti-VEGF Therapeutic Revenue by Region (2024-2029) & (US$ Million)
Table 10. Global Anti-VEGF Therapeutic Revenue Market Share by Region (2018-2024)
Table 11. Global Anti-VEGF Therapeutic Revenue Market Share by Region (2024-2029)
Table 12. Global Anti-VEGF Therapeutic Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 13. Global Anti-VEGF Therapeutic Sales by Region (2018-2024) & (K Units)
Table 14. Global Anti-VEGF Therapeutic Sales by Region (2024-2029) & (K Units)
Table 15. Global Anti-VEGF Therapeutic Sales Market Share by Region (2018-2024)
Table 16. Global Anti-VEGF Therapeutic Sales Market Share by Region (2024-2029)
Table 17. Global Anti-VEGF Therapeutic Sales by Manufacturers (2018-2024) & (K Units)
Table 18. Global Anti-VEGF Therapeutic Sales Share by Manufacturers (2018-2024)
Table 19. Global Anti-VEGF Therapeutic Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Anti-VEGF Therapeutic Revenue Share by Manufacturers (2018-2024)
Table 21. Global Key Players of Anti-VEGF Therapeutic, Industry Ranking, 2021 VS 2022 VS 2024
Table 22. Anti-VEGF Therapeutic Price by Manufacturers 2018-2024 (US$/Unit)
Table 23. Global Anti-VEGF Therapeutic Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Anti-VEGF Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Therapeutic as of 2022)
Table 25. Global Key Manufacturers of Anti-VEGF Therapeutic, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Anti-VEGF Therapeutic, Product Offered and Application
Table 27. Global Key Manufacturers of Anti-VEGF Therapeutic, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Anti-VEGF Therapeutic Sales by Type (2018-2024) & (K Units)
Table 30. Global Anti-VEGF Therapeutic Sales by Type (2024-2029) & (K Units)
Table 31. Global Anti-VEGF Therapeutic Sales Share by Type (2018-2024)
Table 32. Global Anti-VEGF Therapeutic Sales Share by Type (2024-2029)
Table 33. Global Anti-VEGF Therapeutic Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Anti-VEGF Therapeutic Revenue by Type (2024-2029) & (US$ Million)
Table 35. Global Anti-VEGF Therapeutic Revenue Share by Type (2018-2024)
Table 36. Global Anti-VEGF Therapeutic Revenue Share by Type (2024-2029)
Table 37. Anti-VEGF Therapeutic Price by Type (2018-2024) & (US$/Unit)
Table 38. Global Anti-VEGF Therapeutic Price Forecast by Type (2024-2029) & (US$/Unit)
Table 39. Global Anti-VEGF Therapeutic Sales by Application (2018-2024) & (K Units)
Table 40. Global Anti-VEGF Therapeutic Sales by Application (2024-2029) & (K Units)
Table 41. Global Anti-VEGF Therapeutic Sales Share by Application (2018-2024)
Table 42. Global Anti-VEGF Therapeutic Sales Share by Application (2024-2029)
Table 43. Global Anti-VEGF Therapeutic Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Anti-VEGF Therapeutic Revenue by Application (2024-2029) & (US$ Million)
Table 45. Global Anti-VEGF Therapeutic Revenue Share by Application (2018-2024)
Table 46. Global Anti-VEGF Therapeutic Revenue Share by Application (2024-2029)
Table 47. Anti-VEGF Therapeutic Price by Application (2018-2024) & (US$/Unit)
Table 48. Global Anti-VEGF Therapeutic Price Forecast by Application (2024-2029) & (US$/Unit)
Table 49. US & Canada Anti-VEGF Therapeutic Sales by Type (2018-2024) & (K Units)
Table 50. US & Canada Anti-VEGF Therapeutic Sales by Type (2024-2029) & (K Units)
Table 51. US & Canada Anti-VEGF Therapeutic Revenue by Type (2018-2024) & (US$ Million)
Table 52. US & Canada Anti-VEGF Therapeutic Revenue by Type (2024-2029) & (US$ Million)
Table 53. US & Canada Anti-VEGF Therapeutic Sales by Application (2018-2024) & (K Units)
Table 54. US & Canada Anti-VEGF Therapeutic Sales by Application (2024-2029) & (K Units)
Table 55. US & Canada Anti-VEGF Therapeutic Revenue by Application (2018-2024) & (US$ Million)
Table 56. US & Canada Anti-VEGF Therapeutic Revenue by Application (2024-2029) & (US$ Million)
Table 57. US & Canada Anti-VEGF Therapeutic Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 58. US & Canada Anti-VEGF Therapeutic Revenue by Country (2018-2024) & (US$ Million)
Table 59. US & Canada Anti-VEGF Therapeutic Revenue by Country (2024-2029) & (US$ Million)
Table 60. US & Canada Anti-VEGF Therapeutic Sales by Country (2018-2024) & (K Units)
Table 61. US & Canada Anti-VEGF Therapeutic Sales by Country (2024-2029) & (K Units)
Table 62. Europe Anti-VEGF Therapeutic Sales by Type (2018-2024) & (K Units)
Table 63. Europe Anti-VEGF Therapeutic Sales by Type (2024-2029) & (K Units)
Table 64. Europe Anti-VEGF Therapeutic Revenue by Type (2018-2024) & (US$ Million)
Table 65. Europe Anti-VEGF Therapeutic Revenue by Type (2024-2029) & (US$ Million)
Table 66. Europe Anti-VEGF Therapeutic Sales by Application (2018-2024) & (K Units)
Table 67. Europe Anti-VEGF Therapeutic Sales by Application (2024-2029) & (K Units)
Table 68. Europe Anti-VEGF Therapeutic Revenue by Application (2018-2024) & (US$ Million)
Table 69. Europe Anti-VEGF Therapeutic Revenue by Application (2024-2029) & (US$ Million)
Table 70. Europe Anti-VEGF Therapeutic Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Anti-VEGF Therapeutic Revenue by Country (2018-2024) & (US$ Million)
Table 72. Europe Anti-VEGF Therapeutic Revenue by Country (2024-2029) & (US$ Million)
Table 73. Europe Anti-VEGF Therapeutic Sales by Country (2018-2024) & (K Units)
Table 74. Europe Anti-VEGF Therapeutic Sales by Country (2024-2029) & (K Units)
Table 75. China Anti-VEGF Therapeutic Sales by Type (2018-2024) & (K Units)
Table 76. China Anti-VEGF Therapeutic Sales by Type (2024-2029) & (K Units)
Table 77. China Anti-VEGF Therapeutic Revenue by Type (2018-2024) & (US$ Million)
Table 78. China Anti-VEGF Therapeutic Revenue by Type (2024-2029) & (US$ Million)
Table 79. China Anti-VEGF Therapeutic Sales by Application (2018-2024) & (K Units)
Table 80. China Anti-VEGF Therapeutic Sales by Application (2024-2029) & (K Units)
Table 81. China Anti-VEGF Therapeutic Revenue by Application (2018-2024) & (US$ Million)
Table 82. China Anti-VEGF Therapeutic Revenue by Application (2024-2029) & (US$ Million)
Table 83. Asia Anti-VEGF Therapeutic Sales by Type (2018-2024) & (K Units)
Table 84. Asia Anti-VEGF Therapeutic Sales by Type (2024-2029) & (K Units)
Table 85. Asia Anti-VEGF Therapeutic Revenue by Type (2018-2024) & (US$ Million)
Table 86. Asia Anti-VEGF Therapeutic Revenue by Type (2024-2029) & (US$ Million)
Table 87. Asia Anti-VEGF Therapeutic Sales by Application (2018-2024) & (K Units)
Table 88. Asia Anti-VEGF Therapeutic Sales by Application (2024-2029) & (K Units)
Table 89. Asia Anti-VEGF Therapeutic Revenue by Application (2018-2024) & (US$ Million)
Table 90. Asia Anti-VEGF Therapeutic Revenue by Application (2024-2029) & (US$ Million)
Table 91. Asia Anti-VEGF Therapeutic Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 92. Asia Anti-VEGF Therapeutic Revenue by Region (2018-2024) & (US$ Million)
Table 93. Asia Anti-VEGF Therapeutic Revenue by Region (2024-2029) & (US$ Million)
Table 94. Asia Anti-VEGF Therapeutic Sales by Region (2018-2024) & (K Units)
Table 95. Asia Anti-VEGF Therapeutic Sales by Region (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales by Type (2018-2024) & (K Units)
Table 97. Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales by Type (2024-2029) & (K Units)
Table 98. Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue by Type (2018-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue by Type (2024-2029) & (US$ Million)
Table 100. Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales by Application (2018-2024) & (K Units)
Table 101. Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales by Application (2024-2029) & (K Units)
Table 102. Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue by Application (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue by Application (2024-2029) & (US$ Million)
Table 104. Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 105. Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue by Country (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue by Country (2024-2029) & (US$ Million)
Table 107. Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales by Country (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales by Country (2024-2029) & (K Units)
Table 109. Regeneron Pharmaceuticals Company Information
Table 110. Regeneron Pharmaceuticals Description and Major Businesses
Table 111. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Regeneron Pharmaceuticals Recent Developments
Table 114. Bayer Company Information
Table 115. Bayer Description and Major Businesses
Table 116. Bayer Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. Bayer Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Bayer Recent Developments
Table 119. Novartis Company Information
Table 120. Novartis Description and Major Businesses
Table 121. Novartis Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. Novartis Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Novartis Recent Developments
Table 124. Roche Company Information
Table 125. Roche Description and Major Businesses
Table 126. Roche Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 127. Roche Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Roche Recent Developments
Table 129. Biogen Company Information
Table 130. Biogen Description and Major Businesses
Table 131. Biogen Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 132. Biogen Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. Biogen Recent Developments
Table 134. Pfizer Company Information
Table 135. Pfizer Description and Major Businesses
Table 136. Pfizer Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 137. Pfizer Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. Pfizer Recent Developments
Table 139. Coherus BioSciences Company Information
Table 140. Coherus BioSciences Description and Major Businesses
Table 141. Coherus BioSciences Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 142. Coherus BioSciences Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 143. Coherus BioSciences Recent Developments
Table 144. Amgen Company Information
Table 145. Amgen Description and Major Businesses
Table 146. Amgen Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 147. Amgen Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 148. Amgen Recent Developments
Table 149. Bausch Health Companies Company Information
Table 150. Bausch Health Companies Description and Major Businesses
Table 151. Bausch Health Companies Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 152. Bausch Health Companies Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 153. Bausch Health Companies Recent Developments
Table 154. Viatris Company Information
Table 155. Viatris Description and Major Businesses
Table 156. Viatris Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 157. Viatris Anti-VEGF Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 158. Viatris Recent Developments
Table 159. Key Raw Materials Lists
Table 160. Raw Materials Key Suppliers Lists
Table 161. Anti-VEGF Therapeutic Distributors List
Table 162. Anti-VEGF Therapeutic Customers List
Table 163. Anti-VEGF Therapeutic Market Trends
Table 164. Anti-VEGF Therapeutic Market Drivers
Table 165. Anti-VEGF Therapeutic Market Challenges
Table 166. Anti-VEGF Therapeutic Market Restraints
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-VEGF Therapeutic Product Picture
Figure 2. Global Anti-VEGF Therapeutic Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Anti-VEGF Therapeutic Market Share by Type in 2022 & 2029
Figure 4. Aflibercept (Eylea) Product Picture
Figure 5. Ranibizumab (Lucentis) Product Picture
Figure 6. Brolucizumab (Beovu) Product Picture
Figure 7. Others Product Picture
Figure 8. Global Anti-VEGF Therapeutic Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Anti-VEGF Therapeutic Market Share by Application in 2022 & 2029
Figure 10. Macular Edema
Figure 11. Diabetic Retinopathy
Figure 12. Retinal Vein Occlusion
Figure 13. Age-related Macular Degeneration
Figure 14. Others
Figure 15. Anti-VEGF Therapeutic Report Years Considered
Figure 16. Global Anti-VEGF Therapeutic Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Anti-VEGF Therapeutic Revenue 2018-2029 (US$ Million)
Figure 18. Global Anti-VEGF Therapeutic Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 19. Global Anti-VEGF Therapeutic Revenue Market Share by Region (2018-2029)
Figure 20. Global Anti-VEGF Therapeutic Sales 2018-2029 ((K Units)
Figure 21. Global Anti-VEGF Therapeutic Sales Market Share by Region (2018-2029)
Figure 22. US & Canada Anti-VEGF Therapeutic Sales YoY (2018-2029) & (K Units)
Figure 23. US & Canada Anti-VEGF Therapeutic Revenue YoY (2018-2029) & (US$ Million)
Figure 24. Europe Anti-VEGF Therapeutic Sales YoY (2018-2029) & (K Units)
Figure 25. Europe Anti-VEGF Therapeutic Revenue YoY (2018-2029) & (US$ Million)
Figure 26. China Anti-VEGF Therapeutic Sales YoY (2018-2029) & (K Units)
Figure 27. China Anti-VEGF Therapeutic Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Asia (excluding China) Anti-VEGF Therapeutic Sales YoY (2018-2029) & (K Units)
Figure 29. Asia (excluding China) Anti-VEGF Therapeutic Revenue YoY (2018-2029) & (US$ Million)
Figure 30. Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales YoY (2018-2029) & (K Units)
Figure 31. Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue YoY (2018-2029) & (US$ Million)
Figure 32. The Anti-VEGF Therapeutic Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 33. The Top 5 and 10 Largest Manufacturers of Anti-VEGF Therapeutic in the World: Market Share by Anti-VEGF Therapeutic Revenue in 2022
Figure 34. Global Anti-VEGF Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 35. Global Anti-VEGF Therapeutic Sales Market Share by Type (2018-2029)
Figure 36. Global Anti-VEGF Therapeutic Revenue Market Share by Type (2018-2029)
Figure 37. Global Anti-VEGF Therapeutic Sales Market Share by Application (2018-2029)
Figure 38. Global Anti-VEGF Therapeutic Revenue Market Share by Application (2018-2029)
Figure 39. US & Canada Anti-VEGF Therapeutic Sales Market Share by Type (2018-2029)
Figure 40. US & Canada Anti-VEGF Therapeutic Revenue Market Share by Type (2018-2029)
Figure 41. US & Canada Anti-VEGF Therapeutic Sales Market Share by Application (2018-2029)
Figure 42. US & Canada Anti-VEGF Therapeutic Revenue Market Share by Application (2018-2029)
Figure 43. US & Canada Anti-VEGF Therapeutic Revenue Share by Country (2018-2029)
Figure 44. US & Canada Anti-VEGF Therapeutic Sales Share by Country (2018-2029)
Figure 45. U.S. Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 46. Canada Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 47. Europe Anti-VEGF Therapeutic Sales Market Share by Type (2018-2029)
Figure 48. Europe Anti-VEGF Therapeutic Revenue Market Share by Type (2018-2029)
Figure 49. Europe Anti-VEGF Therapeutic Sales Market Share by Application (2018-2029)
Figure 50. Europe Anti-VEGF Therapeutic Revenue Market Share by Application (2018-2029)
Figure 51. Europe Anti-VEGF Therapeutic Revenue Share by Country (2018-2029)
Figure 52. Europe Anti-VEGF Therapeutic Sales Share by Country (2018-2029)
Figure 53. Germany Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 54. France Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 55. U.K. Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 56. Italy Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 57. Russia Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 58. China Anti-VEGF Therapeutic Sales Market Share by Type (2018-2029)
Figure 59. China Anti-VEGF Therapeutic Revenue Market Share by Type (2018-2029)
Figure 60. China Anti-VEGF Therapeutic Sales Market Share by Application (2018-2029)
Figure 61. China Anti-VEGF Therapeutic Revenue Market Share by Application (2018-2029)
Figure 62. Asia Anti-VEGF Therapeutic Sales Market Share by Type (2018-2029)
Figure 63. Asia Anti-VEGF Therapeutic Revenue Market Share by Type (2018-2029)
Figure 64. Asia Anti-VEGF Therapeutic Sales Market Share by Application (2018-2029)
Figure 65. Asia Anti-VEGF Therapeutic Revenue Market Share by Application (2018-2029)
Figure 66. Asia Anti-VEGF Therapeutic Revenue Share by Region (2018-2029)
Figure 67. Asia Anti-VEGF Therapeutic Sales Share by Region (2018-2029)
Figure 68. Japan Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 69. South Korea Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 70. China Taiwan Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 71. Southeast Asia Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 72. India Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 73. Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales Market Share by Type (2018-2029)
Figure 74. Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue Market Share by Type (2018-2029)
Figure 75. Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales Market Share by Application (2018-2029)
Figure 76. Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue Market Share by Application (2018-2029)
Figure 77. Middle East, Africa and Latin America Anti-VEGF Therapeutic Revenue Share by Country (2018-2029)
Figure 78. Middle East, Africa and Latin America Anti-VEGF Therapeutic Sales Share by Country (2018-2029)
Figure 79. Brazil Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 80. Mexico Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 81. Turkey Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 82. Israel Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 83. GCC Countries Anti-VEGF Therapeutic Revenue (2018-2029) & (US$ Million)
Figure 84. Anti-VEGF Therapeutic Value Chain
Figure 85. Anti-VEGF Therapeutic Production Process
Figure 86. Channels of Distribution
Figure 87. Distributors Profiles
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries